Living Cell Technologies Limited (LCT) is a global pioneer in the field of cell encapsulation and implantation for human therapeutics.
Having completed a successful Phase I/IIa clinical trial in Russia, LCT currently has Phase IIb clinical trials underway in New Zealand and Argentina. Safety and preliminary efficacy data generated to date show promise that DIABECELL will change the paradigm for treating diabetes when it becomes the world's first approved porcine cell implant.
On 1 November 2011 LCT and Otsuka Pharmaceutical Factory, Inc. created a new company Diatranz Otsuka Limited (DOL) with cash of $A25,000,000 to accelerate the development and commercialisation of DIABECELL.
Using breakthrough proprietary micro-encapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss.